CD33 Antibodies

Santa Cruz Biotechnology features a diverse variety of CD33 monoclonal antibodies for research in understanding CD33's role in immune regulation. CD33 monoclonal antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). CD33, also known as Siglec-3, is a sialic acid-binding immunoglobulin-like lectin that plays a crucial role in the regulation of immune responses, particularly in myeloid cells. CD33 is involved in the inhibition of immune cell activation and has been implicated in the pathogenesis of various hematological malignancies, making it a significant target for therapeutic interventions. Understanding CD33 function is essential for developing strategies to modulate immune responses in diseases such as acute myeloid leukemia (AML). Research utilizing CD33 monoclonal antibodies can reveal important mechanisms in cellular signaling pathways and immune system regulation. Investigating CD33's role in disease progression can lead to improved therapeutic approaches for various hematological conditions. CD33 expression patterns in different cell types provide valuable information about immune system development and function. Santa Cruz Biotechnology monoclonal antibodies enable researchers worldwide to advance our understanding of CD33's role in human health and disease.